StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX)

Stock analysts at StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX - Get Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a "sell" rating on the stock.

Separately, Needham & Company LLC reissued a "buy" rating and issued a $4.25 price target on shares of OncoCyte in a research note on Tuesday, October 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $4.06.

OncoCyte Trading Down 0.3 %

OCX traded down $0.01 during midday trading on Friday, reaching $3.04. 2,477 shares of the company's stock traded hands, compared to its average volume of 36,576. OncoCyte has a 52 week low of $2.08 and a 52 week high of $4.34. The firm has a fifty day moving average of $3.08 and a two-hundred day moving average of $2.95.

OncoCyte (NASDAQ:OCX - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. The business had revenue of $0.10 million during the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.

Insider Transactions at OncoCyte

In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the firm's stock in a transaction on Wednesday, October 2nd. The stock was acquired at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the purchase, the insider now owns 6,244,405 shares of the company's stock, valued at approximately $18,420,994.75. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CFO Andrea S. James purchased 33,670 shares of the company's stock in a transaction that occurred on Wednesday, October 2nd. The shares were bought at an average price of $2.97 per share, for a total transaction of $99,999.90. Following the purchase, the chief financial officer now directly owns 33,670 shares in the company, valued at approximately $99,999.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of OncoCyte stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the purchase, the insider now owns 6,244,405 shares in the company, valued at $18,420,994.75. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.94% of the company's stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.